Clinical-stage biotechnology company developing next-generation in vivo macrophage cell therapies
Clinical-stage biotechnology company developing next-generation in vivo macrophage cell therapies. Its pullulan-based Myeloid Targeting Platform uses nanoparticles to selectively deliver therapeutic payloads to disease-associated macrophages and dendritic cells, with programs targeting solid tumors and fibrotic diseases.